MedTrace Logo

Using Clinicopathomic Markers to Predict Neoadjuvant Chemotherapy Response in Breast Cancer

NCT04021069 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 800

Last updated 2019-07-16

No results posted yet for this study

Summary

This study examines retrospective clinical data on patients diagnosed with breast cancer and monitor their response to neoadjuvant chemotherapy, incidence of locoregional recurrence, distant metastasis, and disease-free survival. The hypothesis of this study is that breast cancer patients who achieve a pathological complete response (pCR) to neoadjuvant chemotherapy demonstrate distinct clinicopathomic biomarker signatures.

Conditions

  • Breast Cancer
  • Invasive Ductal Breast Carcinoma
  • Invasive Lobular Breast Carcinoma

Interventions

DIAGNOSTIC_TEST

Radiomic, pathomic, and clinical markers

This is a non-interventional study.

Sponsors & Collaborators

  • Sunnybrook Health Sciences Centre

    lead OTHER

Principal Investigators

  • William T. Tran, MRT(T), PhD · Sunnybrook Health Sciences Centre

  • Kasia Jerzak, M.Sc., MD · Sunnybrook Health Sciences Centre

  • Fang-I Lu, MD, FRCPC · Sunnybrook Health Sciences Centre

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-08-30
Primary Completion
2019-12-30
Completion
2024-08-30

Countries

  • Canada

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04021069 on ClinicalTrials.gov